Extended Data Fig. 10: JOSD2OE by AAV9 ameliorated TAC-induced established cardiac dysfunction.
(a) WT mice were undergoing TAC operation for 6 weeks. At TAC 2-week, AAV9 (EV or JOSD2OE, a total dose of 2E + 11 vg, tail vein) were injected. Echocardiography was performed at TAC 0, 4, 6-week. Mice were harvested at TAC 6-week. (b) Ejection fraction (EF), fractional shortening (FS) and ratio of E and A peak velocity (E/A) at TAC 0, 4, 6-week. (c) Representative immunoblot of Flag-JOSD2 in heart tissues since TAC 2-week. (d, e) Representative echocardiographic images of left ventricular M-mode and PW doppler at TAC 0, 4, 6-week. (f) Representative images of whole heart at TAC 6-week. (g) Representative images of HE staining of the heart tissues at TAC 6-week were shown. (h, i) Representative images and quantitative analysis of WAG staining at TAC 6-week. (j, k) Representative images of Masson trichrome staining of the hearts sections and quantitative analysis. (n = 6 for each group. For b, P values were determined by two-way ANOVA with Bonferroni’s correction. For i and k, P values were determined by two-tailed unpaired t-test. For b, i and k, data are presented as mean ± SEM).
